Advanced soft-tissue sarcoma: A disease that is potentially curable for a subset of patients treated with chemotherapy

European Journal of Cancer

Volumn 39, Issue 1, 2003, Pages 64-69

  Blay, J Y ^a,h   Van Glabbeke, M ^b   Verweij, J ^c   Van Oosterom, A T ^d   Le Cesne, A ^e   Oosterhuis, J W ^c   Judson, I ^f   Nielsen, O S ^g  

^a HOSPICES CIVILS DE LYON   (France)

^b EORTC DATA CENTER   (Belgium)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h CENTRE LÉON BÉRARD   (France)

Author keywords

Advanced disease; Chemotherapy; Clinical trials; Long term survivors; Retrospective study; Soft tissue sarcoma

Indexed keywords

CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEX DIFFERENTIATION; SOFT TISSUE SARCOMA; STATISTICAL MODEL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DOXORUBICIN; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SARCOMA; SEX FACTORS; SURVIVAL ANALYSIS; SURVIVORS; TREATMENT OUTCOME;

EID: 0037216150     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00480-X     Document Type: Article

References (25)

1. Van Glabbeke M., van Oosterom A.T., Oosterhuis J.W.et al. Pronostic factors in advanced soft tissue sarcoma (STS). analysis of 2187 patients treated with doxorubicin containing first line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study J. Clin. Oncol. 17:1999;150-157.
2. Pinedo H.M., Bramwell V.H., Mouridsen H.T.et al. Cyvadic in advanced soft tissue sarcoma. a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group Cancer. 53:1984;1825-1832.
3. Mouridsen H.T., Bastholt L., Somers R.et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer Clin. Oncol. 23:1987;1477-1483.
4. Schutte J., Mouridsen H.T., Stewart W.et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. 26:1990;558-561.
5. Santoro A., Tursz T., Mouridsen H.et al. Doxorubicin versus CyVADic versus ifosfamide plus doxorubicin in first line treatment of advanced soft tissue sarcomas. A randomized study of the EORTC Soft tissue and bone sarcoma group. J. Clin. Oncol. 13:1995;1537-1545.
6. Stewart W.P., Verweij J., Somers R.et al. GM-CSF allows safe escalation of dose intensity in metastatic adult soft tissue sarcomas. a study of the European organisation for Research and treatment of Cancer Soft tissue and Bone sarcoma Group J. Clin. Oncol. 11:1993;15-21.
7. Dombernovski P., Mouridsen H., Nielsen O.S.et al. A phase III trial comparing adriamycin versus two schedule of high dose epirubicin in advanced soft tissue sarcomas. Proc. Am. Sco. Clin. Oncol. 14:1995;515.
8. Tursz T., Verweij J., Judson I.et al. Is high dose chemoherapyu of interest in advanced soft tissue sarcomas. An EORTC randomized phase III trial. Proc. Am. Soc. Clin. Oncol. 15:1996;337. (abstr).
9. Edmonson J.H., Ryan L.M., Blum R.G.et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 11:1993;1269-1275.
10. Antman K.H., Crowley J., Balcerzak S.P.et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide an Mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol. 11:1993;1276-1285.
11. Bui B.N., Chevreau C., Demaille M.C., Blay J.Y.et al. A randomized phase III study of MAID vs intensified MAID in patients with advanced soft tissue sarcomas. Proc. Am. Soc. Clin. Oncol. 17:1998;516a. (abstr).
12. Putnam J.B., Roth J.A. Surgical management for pulmonary metastases from sarcomas. Hematol. Oncol. Clin. North Am. 9:1995;869-886.
13. Wiklund T., Saeter G., Strander H.et al. The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience. Eur. J. Cancer. 33:1997;357-361.
14. Rouëssé J.G., Friedman S., Sevin D.M.et al. Preoperative induction chemotherapy in the treatment of locally advanced soft tissue sarcomas. Cancer. 60:1987;296-300.
15. Yap B.S., Sincovics J.G., Burgess M.A., Benjamin R.S., Bodey G.P. The curability of advanced soft tissue sarcomas in adult with chemotherapy. Proc. Am. Soc. Clin. Oncol. 1:1983;239. (abstr).
16. Samuels B., Elias A., Vogelzang N.et al. High dose chemotherapy with ABMT for refractory sarcoma. Proc. Am. Soc. Clin. Oncol. 8:1989;1068. (abstr).
17. Elias A.D., Ayash L.J., Wheeler C.et al. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant. 15:1995;373-379.
18. Dumontet C., Biron P., Bouffet E.et al. High dose chemotherapy with ABMT in soft tissue sarcomas. a report of 22 cases Bone Marrow Transplant. 10:1992;405-408.
19. Kessinger A., Petersen K., Bishop M.et al. High dose therapy with autologous hematopoietic stem cell rescue for patients with metastastic sarcoma. Proc. Am. Soc. Clin. Oncol. 13:1994;1674. (abstr).
20. Mesia R., Sola C., Lopez-Pousa A.et al. High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas. Rev. Clin. Esp. 194:1994;960-965.
21. Blay J.-Y., Bouhour D., Ray-Coquard I., Dumontet C., Philip T., Biron P. High-dose chemotherapy with autologous hepatopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J. Clin. Oncol. 18:2000;3643-3650.
22. Van Oosterom A.T., Verweij J. New drugs for the treatment of sarcomas. Hematol. Oncol. Clin. North Am. 9:1995;909-925.
23. Delaloge S., Yovine A., Taamma A.et al. Ecteinascidin-743. a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity J. Clin. Oncol. 19:2001;1248-1255.
24. Demetri G.D., Seiden M., Garcia-Carbonero R.et al. ET743 shows promising activity in distinct populations of sarcoma patients. summary of 3 phase II trials Proc. Am. Soc. Clin. Oncol. 19:2000;553a. (abstr 2177).
25. LeCesne A.et al. Phase II study of ET743 in advanced soft tisue sarcomab(ASTS) in adults. A STBSG EORTC trial. Proc. Am. Soc. Clin. Oncol. 19:2000;554a. (abstr 2182).